NSE: ANURAS · 16 November 2026
- Anupam Rasayan India has risen 10.48% over 3 trading sessions; today's move is +1.25%.
- Anupam Rasayan India Ltd. submitted revised standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, following the correction of an inadvertent error in the initial filing. The submission includes detailed financial statements and press releases outlining the company's performance for the period. These results provide transparency into the company's revenue and profitability metrics for the second quarter of fiscal 2027.
- Trading volume was 1.35 times the 20-day average daily volume.
Anupam Rasayan India share price: 10.48% rise over 3 trading sessions
Anupam Rasayan India Ltd. (ANURAS) advanced 1.25% today, closing at ₹1,316.80 compared to its previous close of ₹1,300.60. The stock opened at ₹1,308.00 and moved within a intraday range of ₹1,300.00 and ₹1,323.00.
In broader market context, the stock's positive performance diverged from the wider sectoral trend. While the benchmark Nifty index gained 0.58% during the session, the Nifty Metal sector benchmark moved in the opposite direction, declining by 1.50%. Anupam Rasayan's ability to maintain an upward trajectory amidst sectoral weakness points to stock-specific interest, building on prior session returns of 8.22% and a two-session return of 9.12%.
On the corporate and news front, the company recently submitted corrected standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026, following the correction of an inadvertent error on November 6, 2026. While this operational update provides ongoing context regarding the company's financial disclosures, no single same-day catalyst was officially announced to directly trigger today's 1.25% advance, suggesting the price action is largely a continuation of recent positive momentum in specialty chemicals.
7.10 lakh shares traded by 16 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 5.25 lakh shares (1.35 times). The five-day average daily volume was 9.24 lakh shares. Separately, the NSE report for 16 November 2026 showed 2.79 lakh shares delivered, representing 39.33% of that day’s traded volume. The same report recorded 22,949 trades.
The stock advanced 1.25% on moderate volume that exceeded its 20-day average (1.35x) but trailed its 5-day average (0.77x), building upon prior gains of 8.22% in the previous trading day and 13.01% over 5 trading days. In the absence of a same-day news catalyst, the movement appears to reflect continued buying interest and momentum following recent quarterly updates.
Latest Company Developments
Anupam Rasayan India Ltd. submitted revised standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, following the correction of an inadvertent error in the initial filing. The submission includes detailed financial statements and press releases outlining the company's performance for the period. These results provide transparency into the company's revenue and profitability metrics for the second quarter of fiscal 2027.
Financial statement revisions ensure accuracy and provide investors with reliable baseline figures for evaluating the company's valuation and ongoing margin trends.
Anupam Rasayan provided an update on its strategic acquisition of equity shares in Bliss GVS Pharma Limited, marking a key step in expanding its presence into an integrated global pharma platform. The initial announcement was made in late September, establishing contract manufacturing and supply synergies in the life sciences sector. The transaction forms part of the company's broader diversification strategy into pharmaceutical intermediates.
Strategic investments and acquisitions impact the company's long-term capital allocation, market reach, and overall growth trajectory in the life sciences segment.
Revised Unaudited Financial Results (Standalone and Consolidated) of the Companyfor the quarter and half year ended September 30, 2026 with the correction of an inadvertent error.
update on disclosure dated 28 September 2026 on the intimation of acquisition of equity shares of Bliss GVS Pharma Limited.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 0.43% on 30 September 2026. This compares with 0.19% on 30 June 2026, a change of +0.24 percentage points.
The filing reported 20 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution and financial impact of the Bliss GVS Pharma equity acquisition
- Volume trends relative to the 20-day average of 1.35x to gauge continued cash participation
- Management commentary and delivery percentages following recent Q2 FY27 earnings disclosures
- Performance trends relative to sector benchmarks like Nifty Metal and broader market indices
Other Dated Coverage
More Anupam Rasayan India news and dated analysis →
Frequently Asked Questions
What is the latest Anupam Rasayan India company news?
Anupam Rasayan India Ltd. submitted revised standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, following the correction of an inadvertent error in the initial filing. The submission includes detailed financial statements and press releases outlining the company's performance for the period. These results provide transparency into the company's revenue and profitability metrics for the second quarter of fiscal 2027.
How strong was Anupam Rasayan India’s trading volume?
7.10 lakh shares traded, 1.35 times the 20-day average daily volume. The price and volume data are dated 16 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.
